Anixa Biosciences wins Mexican patent for breast cancer vaccine technology

• Anixa Biosciences reported issuance of Mexican Patent No. 432748 covering key aspects of its breast cancer vaccine technology.
• Patent provides intellectual property protection in Mexico into 2040.
• Vaccine targets human α-lactalbumin, a lactation-associated protein aberrantly expressed in some breast cancers.
• Program delivered positive Phase 1 results, meeting primary endpoints with immune responses in 74% of participants.
• Anixa is preparing for a Phase 2 clinical trial while expanding international patent coverage for the vaccine program into the 2040s.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.